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Abstract
Background: Dabigatran etexilate may be underutilized in geriatric patients because of inadequate clinical
experience in individuals with severe renal impairment and post-marketing reports of bleeding events. Assessing
the degree of anticoagulation may improve the risk:benefit ratio for dabigatran. The aim of this prospective study
was to identify whether therapeutic drug monitoring of dabigatran anticoagulant activity using a chromogenic
anti-factor IIa assay is a viable option for therapy individualization.
Methods: Plasma dabigatran concentration was assessed in nine patients with nonvalvular atrial fibrillation aged 75 years
or older currently receiving dabigatran etexilate for prevention of stroke, using an anti-factor IIa chromogenic assay and
HPLC-MS/MS. Trough concentrations were evaluated on two separate occasions to determine intrapatient variation.
Results: Blood was collected at 13.1 ± 2.3 h (mean ± SD) post dose from patients prescribed dabigatran etexilate
150 mg twice daily (5/9 patients) or dabigatran etexilate 75 mg twice daily (4/9 patients). Results from the anti-factor IIa
chromogenic assay correlated with dabigatran concentrations as assessed by HPLC-MS/MS (r2 = 0.81, n = 16). There was
no correlation between dabigatran trough values taken at separate visits (r2 = 0.002, n = 7). Furthermore, there was no
correlation found between the drug concentrations and patients’ renal function determined by both creatinine and
cystatin-C based equations. None of the patients enrolled in the study were in the proposed on-therapy trough range
during at least one visit.
Conclusion: The chromogenic anti-factor IIa assay demonstrated similar performance in quantifying dabigatran plasma
trough concentrations to HPLC-MS/MS. Single measurement of dabigatran concentration by either of two methods
during routine visits may not be reliable in identifying patients at consistently low or high dabigatran concentrations.
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Background
Dabigatran possesses many of the attributes of an ideal
anticoagulant for stroke prevention in nonvalvular atrial
fibrillation (NVAF) including predictable pharmacokinet-
ics and lack of the requirement for routine monitoring
[1–3]. While routine monitoring may be unnecessary,
assessment of degree of anticoagulation may be important
in populations at risk of altered pharmacokinetics [4, 5].
Since the FDA approval of dabigatran etexilate in 2010,
several regulatory agencies have issued warnings regarding
the risk of bleeding, analogous to other target specific oral
anticoagulants and vitamin K antagonists. The majority of
hemorrhagic events linked to dabigatran have been
reported in geriatric patients with renal dysfunction [6–9].
Although the landmark Randomized Evaluation of Long-
Term Anticoagulation Therapy (RE-LY) trial found dabi-
gatran etexilate 150 mg twice daily to be superior to
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warfarin; it has been difficult to extrapolate the results to
the geriatric population or to patients with severe renal
impairment. A post-hoc analysis of the RE-LY trial re-
vealed that patients ≥ 75 years of age had a greater inci-
dence of gastrointestinal bleeding (but not intracranial)
compared with patients on warfarin (1.85 %/year versus
1.25 %/year, respectively, p < 0.001) [10]. Furthermore, an
increased risk of bleeding was identified in elderly patients
irrespective of renal function [11]. Dabigatran etexilate is
underutilized in geriatric patients because of insufficient
clinical experience with dosing recommendations in se-
vere renal impairment and post-marketing reports of
bleeding complications [6–8, 12–18]. The mean age of
RE-LY patients was 71.5 years old and the mean creatinine
clearance (CrCl) was approximately 70 mL/min [19].
Patients with a CrCl < 30 mL/min were excluded from
RE-LY. Moreover, the FDA approval of dabigatran etexi-
late dosing regimen for patients with severe renal dysfunc-
tion was supported by pharmacokinetic modeling based
on data from middle-aged patients rather than actual clin-
ical outcome [20–23]. The European Medicines Agency
(EMA) considers dabigatran etexilate as contraindicated
in patients with a CrCl < 30 mL/min and patients with a
CrCl < 50 mL/min should receive 110 mg twice daily [24].
Collectively, these data suggest that the ability to gauge
the degree of anticoagulation in the geriatric patient popu-
lation may be beneficial.
There are a number of routine coagulation tests used
in clinical practice; however, few are useful for quantita-
tive assessment of dabigatran [5, 25]. The chromogenic
anti-factor IIa assay has been successfully used for thera-
peutic drug monitoring of parenteral direct thrombin
inhibitors and is insensitive to lupus anticoagulant or
genetic coagulation deficiencies [26, 27]. Very little data
have been published on the use of chromogenic anti-
factor IIa assay and its correlation with HPLC-MS-MS
measurement of dabigatran [28]. The aim of this pro-
spective pilot study was to evaluate the utility of the
chromogenic anti-factor IIa assay for monitoring dabiga-
tran therapy and the intra- and interpatient variability of
trough concentrations in elderly patients with atrial
fibrillation.
Methods
A prospective study of nine geriatric patients was
performed to assess dabigatran plasma trough concen-
trations using HPLC-MS/MS and the chromogenic anti-
factor IIa quantification methods on two separate visits
to the clinic. Male and female patients ≥ 75 years of age
with NVAF currently receiving dabigatran etexilate mes-
ylate (dabigatran prodrug) for the prevention of stroke
were eligible for inclusion. Patients with a creatinine
clearance of less than 15 mL/min were excluded since
data are extremely limited and the use of dabigatran
etexilate is contraindicated in this population (based on
the United States product labeling) [29]. Patients with
hemorrhagic disorders or baseline platelet count of less
than 100,000 per liter, on hemodialysis, or with moder-
ate or severe liver impairment (Child Pugh Score of B or
greater) or those on strong P-glycoprotein inhibitors and
inducers (i.e., amiodarone, clarithromycin, dronederone,
ketoconazole, quinidine, rifampin, verapamil, and St.
John’s wort) were excluded. Dabigatran etexilate should
be avoided with rifampin due to significant reduction in
area under the curve (AUC) and maximum serum con-
centration (Cmax) (66 and 67 %, respectively) [29]. While
not contraindicated with P-glycoprotein inhibitors, the
use of dabigatran etexilate with these agents should be
carefully monitored due to increased AUC and Cmax.
Furthermore, in the setting of moderate-to-severe
renal dysfunction and a P-glycoprotein inhibitor, dabi-
gatran etexilate dose reductions should be considered
[29]. The protocol was approved by the Rutgers
University Institutional Review Board (Protocol # 13–
503) and all patients signed an informed consent be-
fore participating in the study.
Patient dosing
The morning of study initiation, consenting patients
were instructed to hold the morning dabigatran etexilate
dosage until a blood sample was obtained at the physi-
cian’s office. Once venous blood samples were drawn,
the patient was instructed to take his/her dose. Patient
demographics and concomitant medications were col-
lected. The process was repeated on the patient’s next
scheduled visit, a minimum of 1 month apart.
Sample collection
Venous blood samples were taken just prior to the
morning dose. Approximately 5 mL was collected in
EDTA tubes for dabigatran plasma concentration meas-
urement by HPLC-MS/MS. Another 5 mL was collected
in 3.2 % tri-sodium citrate tubes (blood:citrate ratio 9:1)
as recommended by the manufacturer for chromogenic
assay. The samples were centrifuged at 2500 × g for
20 min and the plasma was kept on ice for a max of 1 h.
Samples were kept frozen at –80 °C until assessment.
Quantitation of dabigatran
Dabigatran concentration in plasma samples was directly
measured using a validated HPLC-MS/MS technique
(modified from Delavenne et al.) [30] and estimated
using a chromogenic anti-factor IIa assay (Hyphen
Biomed, Neuville-sur-Oise, France). Plasma samples or
standards (100 μL) were mixed with 10 μL of an internal
standard (13C6-dabigatran 1 μg/mL). Analytes were iso-
lated from plasma using protein precipitation with 400 μL
methanol/0.1 N HCl (90:10). After centrifugation, a
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100 μL aliquot of supernatant was taken for the injection,
and the injection volume was 20 μL. A Thermo LTQ mass
spectrometer was interfaced to a Finnigan Surveyor Auto-
sampler plus and Finnigan Surveyor MS Pump plus for
separation and quantitation of dabigatran. Separation was
completed using Betasil Phenyl/Hexyl column (3 μm,
100 × 4.6 mm, Thermo Scientific) and a gradient flow of
water and methanol with 0.1 % formic acid. Electrospray
ionization source was used to ionize the dabigatran before
introduction into the mass spectrometer. Quantification
was performed by addition of 472.2– > 324.2 and
472.2– > 306.1 and 472.2– > 289.1 m/z for dabigatran and
478.3– > 330.2 and 478.3– > 295.1 m/z for the internal
standard. The calibration curves were linear over a con-
centration range of 4–1000 ng/mL.
Chromogenic anti-IIa assay
Dabigatran activity was quantified using a BIOPHEN
DTI kit (Aniara, West Chester, OH). Plasma samples,
dabigatran calibrators or quality controls (50 μl) were
mixed with 50 μl of thrombin chromogenic substrate at
37 °C for 1 min in a 96-well plate. The mixture was then
incubated at 37 °C for 2 min after adding 50 μl of pre-
heated purified human thrombin. Activity was measured
spectrophotometrically at 450 nm (SpectraMax 5,
Molecular Devices, Sunnyvale, CA) in the presence of
20 % of acetic acid and adjusted for sample blanks and
extrapolated from a standard curve. Samples were run in
duplicate. The limit of detection was 14.6 ng/mL and
the dynamic range from 0 to 500 ng/mL.
Assessment of renal function
Both serum creatinine and cystatin-C were measured in
order to estimate renal function using the Cockcroft-
Gault ([140 – age [years] × total body weight]/0.72 × sCr
(mg/dL)) × 0.85 [if female]) and CKD-EPI (127.7 × Cysta-
tin C-1.17 × age-0.13 × 0.91 [if female] × 1.06 [if African
American]) equations, respectively [31, 32]. Of note,
Cockcroft-Gault was the method used to estimate renal
function in RE-LY, [19] the landmark trial leading to the
approval of dabigatran etexilate for prevention of stroke
and systemic embolism in patients with NVAF. Serum
creatinine levels were measured using a kit based on the
Jaffe reaction (Pointe Scientific, Canton, MI). Briefly,
190 μl of pre-heated working reagent including 5 vol-
umes of alkaline buffer and 1 volume of picric acid
(40 mM) were added to 10 μl of samples, creatinine
standard or blank serum. The mixture was incubated at
37 °C for 1 min and the change in optical density was
measured at 510 nm over 3 min.
Cystatin C levels were quantified using a Quantikine
ELISA kit according to the manufacturer’s recommenda-
tions (R&D Systems, Minneapolis, MN). Samples or
cystatin C standards (50 μl) were added to a 96-well
plate coated with an antibody specific for human cysta-
tin C and incubated at 2–8 °C for 3 h. After washing,
cystatin C conjugate was then added to compete for
binding with the antibody. Following incubation, wash-
ing and addition of substrate solutions (stabilized hydro-
gen peroxide and tetramethylbenzidine), the stop
solution (2 N sulfuric acid) was added and the optical
density was measured at 450 nm and 570 nm. Concen-
trations of cystatin C were extrapolated from the stand-
ard curve. Samples were run in duplicate. Renal function
was assessed at each visit.
Data analysis
All data were analyzed using descriptive statistics. Cat-
egorical data were reported as proportions and continu-
ous data as the mean or median as appropriate. Pearson
correlation coefficients were calculated for the relation-
ship between HPLC-MS/MS and chromogenic assay
dabigatran trough levels and estimates of renal function.
Bland-Altman analysis and linear regression were per-
formed to assess the strength of agreement and propor-
tionality bias between HPLC-MS/MS and chromogenic
anti-IIa measures of dabigatran levels. Correlation of
dabigatran trough levels between visits was also evalu-
ated. Trough levels were also compared to proposed
dabigatran on target range (30 ng/mL – 130 ng/mL)
[33]. Analysis was performed using SAS 9.2 (SAS Insti-
tute, Cary, NC) or SPSS version 21 (IBM Corporation,
Armonk, NY).
Results
Nine patients were enrolled, seven patients returned for
a second visit. All patients were on dabigatran etexilate
therapy for a minimum of one month before initiation
of the study. Patient characteristics are summarized in
Table 1. Blood was collected at 13.1 ± 2.3 h (mean ± SD)
post dose from patients receiving dabigatran etexilate
150 mg twice daily (5/9 patients) or dabigatran etexilate
75 mg twice daily (4/9 patients). Results from the anti-
IIa chromogenic assay correlated with dabigatran
concentrations as assessed by HPLC-MS/MS (r2 = 0.81,
n = 15; Fig. 1). In addition, the Spearman’s rho yielded
similar results (rho = 0.91). The Bland-Altman plot
shows a very high limit of agreement defined by the
mean ± 1.96*SD (Fig. 2). The mean bias present was 0.86
and the limits of agreement were 93.0 and – 91.0. The
linear regression of the Bland-Altman plot did not sug-
gest any significant proportionality bias (equation; Y =
0.006545*X – 0.1945; p = 0.9583). High intrapatient
variability in dabigatran trough plasma concentrations
was observed (r2 = 0.002, p = ns; n = 7; Fig. 3). All the
patients enrolled in the study were not within the pro-
posed on-therapy range [33] during at least one study
visit. Seven patients had a dabigatran level exceeding
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130 ng/mL and three patients had a level of less than
30 ng/mL during at least one of the recorded visits.
Baseline creatinine based (Cockcroft-Gault) and
cystatin-C based estimates (CKD-EPI) of renal function
had no-to-poor correlation with plasma dabigatran
concentrations (r = 0.07 and – 0.26, p = ns for both;
respectively).
Discussion
There is a widely held view that the target specific oral an-
ticoagulants, including dabigatran etexilate, have a pre-
dictable response and do not require monitoring;
however, data suggest significant interpatient variability in
pharmacokinetics [34, 35]. In addition, the landmark RE-
LY trial suggests low trough concentrations (rapid de-
crease in the probability of stroke from a concentration of
zero through approximately 70 ng/mL) [36, 37] were asso-
ciated with reduced efficacy and high concentrations were
associated with an increased risk of bleeding [4]. Chan
and colleagues measured the Hemoclot® assay at baseline
and every 2 months for up to 4 visits in 100 patients
(mean age 69.9 years) with atrial fibrillation [35]. They re-
ported a large intrapatient variability in Hemoclot® levels
(geometric coefficient of variation 32 – 40 %). The authors
concluded that a single Hemoclot® measurement is not
reliable in identifying patients with consistently high or
low dabigatran exposure. Some concerns have been raised
regarding the large variation in trough dabigatran levels
seen between visits in the Chan and colleagues study [38].
These concerns included timing of trough sample, stability
of plasma stored at -80 °C, performance of the analysis on
the same run, and lack of outcome data. Arguably, the
most important concern is the lack of stringent timing of
trough levels. While measuring trough levels at 12 ± 1 h is
ideal, when relying on patient reported drug administra-
tion in clinical practice this criteria is difficult to enforce.
Patient reported adherence is inherently a limitation and
may result in measurement bias. Similar to the Chan and
colleagues study, our pilot study found that in geriatric pa-
tients there was large intrapatient variability in dabigatran
exposure as measured by chromogenic anti-IIa assay and
HPLC MS/MS. Specifics on last dose intake in the current
study may be found in Additional file 1.
Fig. 1 The relationship between plasma dabigatran concentrations
determined by chromogenic anti-IIa assay and HPLC-MS-MS. Solid
line – linear regression y = 0.9053x + 16.11, r2 = 0.81
Fig. 2 Bland-Altman plot is shown for dabigatran levels by HPLC
MS/MS and chromogenic anti-factor IIa (diff, difference; n = 16)
Table 1 Patient demographic and dabigatran dosing
characteristics
Characteristic Value
Mean Age ± SD (years) 81.3 ± 4.5
Female (%) 44.5
Mean time after last dabigatran dose ± SD (hours) 13.1 ± 2.3
Mean weight ± SD (kg) 83.0 ± 21.1
Body mass index ± SD (kg/m2) 28.9 ± 4.7
Baseline Renal Clearance ± SD (mL/min)
Cockcroft-Gault 68.4 ± 28.4
CKD-EPI 40.9 ± 12.3
Dabigatran dosage, n (%)
75 mg twice daily 4 (44.4)
150 mg twice daily 5 (55.6)
Cormorbidities (n, %)
Chronic obstructive pulmonary disease 3 (33.3)
Diabetes Mellitus 4 (44.4)
Heart Failure 3 (33.3)
Malignancy 2 (22.2)
Thyroid Disease 4 (44.4)
Coronary Artery Disease 2 (22.2)
Mean HPLC-MS/MS dabigatran level ± SD (ng/mL)a 161.1 ± 104.1
Mean chromogenic anti-IIa dabigatran level ± SD (ng/mL)a 161.9 ± 104.8
aPooled data from all office visits
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Vulnerable populations such as the elderly and
patients with renal impairment have the potential to ex-
hibit exaggerated responses to dabigatran [11, 39, 40].
Dabigatran etexilate, a prodrug, completes its bioconver-
sion in the liver and approximately 20 % is conjugated
with glucuronic acid and excreted via the biliary system
[2, 41]. Dabigatran etexilate requires conversion via es-
terase hydrolysis to the active form (dabigatran) [2].
Genetic factors, such as polymorphisms in carboxylester-
ase 1, may also be responsible for interpatient variability
[42]. There may also be variability in drug exposure sec-
ondary to inhibition or induction of the efflux trans-
porter P-glycoprotein, as dabigatran etexilate is substrate
of this transport protein [29, 43]. While these factors ex-
plain the interpatient variability that may be present,
they do not account for the intrapatient variability ob-
served between clinic visits in this study.
No therapeutic range has been established for dabiga-
tran; however, a target plasma dabigatran trough con-
centration of 30 – 130 ng/mL has been suggested by
Chin and colleagues [33]. Some limitations to using this
range include derivation from pharmacokinetic simula-
tions and lack of prospective studies confirming that the
range predicts clinical outcomes. However, with the lack
of definitive data, this range provides a good starting
point and there are data from landmark trials confirming
dabigatran levels may be predictive of thrombosis and
bleeding [4]. For example, patients in the RE-LY trial
with any major bleeding had a higher dabigatran trough
concentration (113 ng/mL) compared to patients without
a bleeding event (72.8 ng/mL) [4]. Furthermore, age was
the most important covariate. Collectively, these data may
be used to construct a dabigatran concentration-to-assay
result curve to predict drug exposure and predict risk of
bleeding [44]. In our analysis, we found that all patients
were not in the on-therapy range on at least one of the
two visits. Furthermore, 4 out of 9 patients had dabigatran
trough levels exceeding 200 ng/mL during at least one
visit and trough levels above 200 ng/mL are associated
with an increased risk of bleeding [45]. These results are
concerning and suggest geriatric patients may be at an
unecessary risk of treatment failure and/or bleeding.
Estimating renal function in the elderly is challenging
and many of the currently available methods are
inaccurate [46]. Unlike creatinine, cystatin C levels are
unaffected by age, muscle mass, gender, and race [32].
We were not able to appreciate any significant correl-
ation with either creatinine or cystatin C based estimates
of renal function with dabigatran trough concentrations.
Based on this finding, additional research is warranted
to identify which estimate renal function leads to the se-
lection of the most appropriate dose or if age alone is
sufficient to suggest a dosage reduction [47, 48]. Current
FDA and EMA recommendations for dosing dabigatran
etexilate in renal disease advocate using the Cockcroft-
Gault equation to estimate renal function and clinicians
should not deviate from this strategy [24, 29]. Hellden
and colleagues investigated the impact of using the
Modified Diet in Renal Disease 4 (MDRD4 equation to
estimate glomerular filtration rate and subsequent dose
adjustment in the elderly population (defined as age >
65 years) [49]. Their findings suggest that the MDRD4
would result in higher recommended doses of dabigatran
etexilate to elderly patients versus Cockcroft-Gault,
particularly in women. The increased dose may increase
the risk of toxicity, hence these findings suggest contin-
ued use of Cockcroft-Gault to estimate renal function
for dabigatran etexilate dosing.
These data support further evaluation of strategies to
individualize treatment. The literature on coagulation
monitoring to guide dabigatran therapy is evolving with
several studies and comprehensive reviews now pub-
lished [4, 5, 34, 44, 50–55]. Evidence supports that dabi-
gatran levels are correlated to bleeding risk and efficacy
[4]. Furthermore, in an sub-analysis of the RE-LY trial, a
plasma concentration at trough between 90 and 140 ng/
mL provided the best benefit/risk ratio in patients with
NVAF,[56] although other authors have suggested other
on-target ranges [33, 57]. Tailoring dabigatran etexilate
dose according to patient risk (i.e., age, renal function) is
essential to balance the benefit:risk of thrombosis and
bleeding [58]. Adding the ability to assess degree of
anticoagulation has the potential to further improve the
benefit:risk ratio of dabigatran and warrants consider-
ation especially in special populations such as the geriat-
ric population [59, 60].
This study provides important information obtained
from ‘real world’ use of dabigatran etexilate in geriatric
patients. Chromogenic anti-IIa assay correlates with
Fig. 3 Individual dabigatran plasma trough concentration measured on
two separate occasions using HPLC MS-MS (n= 7). High inter- and
intrapatient variability was observed. Conceptually, due to this variability,
the clinical application of therapeutic drug monitoring is challenging.
Shaded area represents the on-therapy range (30 ng/mL to 130 ng/mL)
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HPLC MS/MS measured dabigatran concentrations and
may be useful for quantitative measurement; however,
the intrapatient variability of dabigatran concentrations
may make clinical application challenging. The fre-
quency of patients outside a proposed therapeutic win-
dow suggests there may be opportunity for improvement
of dosing strategy to further enhance the risk versus
benefit ratio of dabigatran. Glucuronidation is the major
metabolic pathway of dabigatran. The major metabolite of
dabigatran, 1-O-acylglucuronide, and its isomers result in
equipotent prolongation of the activated partial thrombo-
plastin time [41, 61]. Acylglucuronides accounted for
2.0 % of the dose in plasma at 2 h and 4.3 % at 4 h post
administration of intravenous dabigatran [41]. The acyl-
glucuronide metabolites may contribute to the overall
clinical effect of dabigatran and can explain some of the
difference between HPLC-MS/MS detection of dabigatran
and the chromogenic measurement of anti-IIa activity if
there is interpatient variability in glucuronidation. Of note,
previous studies suggest that age does not significantly in-
fluence glucuronidation [62, 63].
Certain limitations of our study should be acknowl-
edged. Although the chomogenic anti-factor II assay
may be performed manually or using an automated coa-
gulometer as indicated in the assay specifications, man-
ual methods may be a potential source of measurement
bias. The timing of trough levels was often not within
1 h of the next scheduled dose due to patient availability,
as suggeted to be optimal for pharmacokinetic studies
[50]. Our data reflects a practical scenario that resembles
the ‘real world’ clinical setting. Furthermore, data sup-
port that sampling within 6 h of the next scheduled dose
will still provide a value within the 80 % confidence
interval for the true trough value as was discussed by
Chan and colleagues [22]. When planning to measure
dabigatran levels it is paramount to educate the patient
on the importance of accurately documenting the last
intake of medication. In addition, scheduling patient
visits according to their usual drug administration
schedule may enhance the accuracy of trough levels. An-
other strategy involves collaboration of clinicians with
laboratories or anticoagulation clinics. Patients can be
instructed to hold their dabigatran etexilate dose until
their office visit where administration can be directly ob-
served. Following directly observed administration of
dabigatran etexilate, the office staff can schedule an ap-
pointment for the patient to present to the laboratory or
clinic for their blood to be drawn.
This study found no correlation between dabigatran
trough levels taken at two different patient visits; however,
the limited sample size requires future studies to confirm
this finding. Ultimately, a large controlled study is neces-
sary to confirm if a monitoring strategy will improve dos-
age selection and dabigatran treatment outcomes.
Conclusion
Chromogenic anti-factor IIa assay demonstrated similar
performance in quantifying dabigatran plasma trough
concentrations to HPLC-MS/MS. All geriatric patients
were not within the on-therapy trough range during at
least one visit. Routine adjustment of dosages based on a
single measurement of trough concentration may not be
appropriate due to significant intrapatient variation.
Given the large proportion of patients falling outside the
on-therapy range and the high variability observed in
this pilot study, larger clinical studies can be recom-
mended to determine the clinical utility of concentration
monitoring in the outpatient setting.
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